HC Wainwright Raises Earnings Estimates for Upstream Bio

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Upstream Bio to a loss of $3.01 per share from $3.09, while maintaining a Buy rating and an $18 price target.
• Upstream Bio reported a quarterly loss of $0.75 per share, missing the $0.73 consensus estimate; revenue of $0.40 million also fell short of the $0.55 million expected.
• Analyst views are mixed: MarketBeat lists a consensus Hold rating and $26.67 target price. Shares opened at $2.86, near the stock’s 52-week low of $2.68.

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - HC Wainwright increased their FY2026 earnings per share estimates for Upstream Bio in a report released on Wednesday, November 11th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($3.01) for the year, up from their prior estimate of ($3.09). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Upstream Bio's current full-year earnings is ($2.88) per share. HC Wainwright also issued estimates for Upstream Bio's Q4 2026 earnings at ($0.78) EPS, FY2027 earnings at ($3.21) EPS, FY2028 earnings at ($3.07) EPS, FY2029 earnings at ($3.54) EPS and FY2030 earnings at ($3.61) EPS.

Other analysts have also issued research reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the company a "neutral" rating in a research note on Friday, August 14th. Truist Financial lowered their price target on shares of Upstream Bio to $25.00 and set a "buy" rating for the company in a report on Tuesday, August 11th. Wall Street Zen lowered shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Upstream Bio has a consensus rating of "Hold" and a consensus target price of $26.67.

Upstream Bio Stock Down 10.6%

Shares of NASDAQ:UPB opened at $2.86 on Friday. Upstream Bio has a 52-week low of $2.68 and a 52-week high of $33.68. The company has a 50 day moving average of $4.30 and a two-hundred day moving average of $8.25.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.55 million. Upstream Bio had a negative return on equity of 57.09% and a negative net margin of 5,712.33%.

Institutional Investors Weigh In On Upstream Bio

Hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new position in shares of Upstream Bio in the 2nd quarter valued at approximately $33,000. Persistent Asset Partners Ltd purchased a new position in shares of Upstream Bio during the 2nd quarter valued at approximately $34,000. The Manufacturers Life Insurance Company boosted its stake in shares of Upstream Bio by 51.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 15,338 shares of the company's stock valued at $138,000 after buying an additional 5,191 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Upstream Bio during the second quarter worth approximately $78,000. Finally, Voya Investment Management LLC acquired a new stake in shares of Upstream Bio during the third quarter worth approximately $57,000.

About Upstream Bio

Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.